Why the study?
Surgical aortic valve replacement has been the only curative guideline-recommended therapy for native aortic regurgitation, while transcatheter options remain limited by anatomic constraints.
Does transfemoral J-Valve transcatheter heart valve implantation provide safe and effective treatment in high-risk patients with symptomatic, severe native aortic regurgitation?
Does transfemoral J-Valve transcatheter heart valve implantation provide safe and effective treatment in high-risk patients with symptomatic, severe native aortic regurgitation?
Transfemoral J-Valve implantation demonstrates preliminary safety and effectiveness with favorable 1-year outcomes and stable hemodynamics in high-risk patients with severe native aortic regurgitation.
Answers are grounded in this paper and cite their sources.
Supports preliminary safety of J-Valve in high-risk native AR; leaves open need for randomized trials before practice change.
Background Clinically significant native aortic regurgitation (AR) increases with age. Surgical aortic valve replacement has been the only curative guideline-recommended therapy, while transcatheter options remain limited by anatomic constraints. Methods The J-Valve early feasibility study (NCT06034028) evaluated the safety and effectiveness of transfemoral J-Valve transcatheter heart valve implantation in patients with symptomatic, severe native AR. The prospective single-arm study enrolled 25 patients with symptomatic, severe, native AR deemed high risk for surgical aortic valve replacement at 8 centers. Clinical and echocardiographic assessments were performed at baseline, 30 days, 6 months, and 1 year with independent core laboratory and clinical events committee adjudication. The primary effectiveness end point was a non-hierarchical composite of all-cause mortality or disabling stroke at 30 days. Results Mean age was 80.6 ± 4.3 years; 76% were male; 100% were New York Heart Association (NYHA) class II/III; mean Society of Thoracic Surgeons-Predicted Risk of Mortality (STS-PROM) score was 5.6 ± 4.5%. Successful implantation occurred in 92% (23/25). The primary end point occurred in 2 patients (8.0%). All-cause mortality was 4.0% at 30 days and 1 year, with no cardiovascular-related deaths. Two strokes (1 disabling) (8.2%) and 2 new pacemaker implantations (10%) occurred within 30 days. At 1 year, none/trace AR was present in 95.5% (21/22) and mild AR in 4.5% (1/22), with a mean gradient of 5.5 ± 1.7 mm Hg, and an effective orifice area of 2.48 ± 0.53 cm 2 . Reverse left ventricular (LV) remodeling was evident at 30 days with sustained reductions in LV end-diastolic and end-systolic volume indices to 1 year. NYHA class improved in 72.7% (16/22) of patients, with 95.5% (21/22) in NYHA class I/II at 1 year. Conclusions This study demonstrates preliminary safety and effectiveness of the J-Valve in high-risk patients with severe AR, with favorable 1-year outcomes and stable hemodynamic performance.
No takes yet. Share an insight, caveat, or question.
Kereiakes et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: